… Eligible patients were randomized to olaparib tablets 300 mg twice … Adverse events (AEs)
should be manageable over time and not … therapy in BRCA-mutated advanced ovarian cancer …

… DNA double-strand break repair in BRCA mutated (mut) cancers [… olaparib (capsules)
compared with placebo [7, 8], olaparib … the formulation administered, adverse events (AEs) were of …

… alterations in DNA repair genes. To facilitate continued … common adverse events (AEs)
and events of special interest. … Alternatively, patients could also take olaparib tablets with a …

… 2 : 1 to maintenance olaparib tablets 300 mg twice daily or … non-BRCA-mutated cohort
were randomized to olaparib and … achieved without detrimental effects on patients’ HRQoL or …

… AEs occurred in 49% and 43% of the olaparib plus bevacizumab and placebo plus bevacizumab
groups, and SAEs in 24% of both groups. AEs … manage adverse reactions to olaparib [9…

… -up of 41 months, patients treated with olaparib had a 70% … , and adverse events (AEs) were
consistent with olaparib's … of olaparib tablets as a maintenance monotherapy in patients who …

… with high-grade epithelial PSR ovarian cancer received oral olaparib 300 mg (tablet … in
terms of adverse events (AE) and serious AEs, laboratory analyses, and vital signs. AEs were …

… the combination of olaparib (300 mg, tablets twice daily) and … Table 3 summarizes adverse
events in PARPi maintenance … in patients (pts) with advanced triple-negative breast cancer or …

… that led to the regulatory approvals for olaparib, niraparib, and … The median time to first onset
of nausea with olaparib tablets … of patients on niraparib in the first-line maintenance therapy …

… Proper management of olaparib/bevacizumab-related adverse events … of BRCA mutated
FIGO stage III or IV EOC, as a switch … Taking olaparib tablets after breakfast and dinner can also …